Vancity Investment Management Ltd trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 111,662 shares of the medical research company’s stock after selling 6,371 shares during the quarter. Edwards Lifesciences accounts for 1.3% of Vancity Investment Management Ltd’s portfolio, making the stock its 26th largest holding. Vancity Investment Management Ltd’s holdings in Edwards Lifesciences were worth $9,519,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Level Four Advisory Services LLC boosted its stake in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after buying an additional 119 shares in the last quarter. Colonial Trust Co SC lifted its holdings in shares of Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after acquiring an additional 120 shares during the period. Evermay Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 4.0% during the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 128 shares during the period. Florida Trust Wealth Management Co boosted its stake in shares of Edwards Lifesciences by 1.5% in the 4th quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock valued at $751,000 after purchasing an additional 132 shares in the last quarter. Finally, McIlrath & Eck LLC grew its holdings in shares of Edwards Lifesciences by 14.6% in the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after purchasing an additional 135 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.
Edwards Lifesciences Trading Up 1.0%
Shares of NYSE EW opened at $87.51 on Friday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $89.60. The company has a 50-day moving average of $83.27 and a two-hundred day moving average of $83.11. The company has a market cap of $50.39 billion, a PE ratio of 46.55, a P/E/G ratio of 2.17 and a beta of 0.87. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.
Analysts Set New Price Targets
A number of brokerages recently issued reports on EW. TD Cowen reiterated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research note on Wednesday, April 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.96.
Check Out Our Latest Stock Report on EW
Insider Transactions at Edwards Lifesciences
In other news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 81,038 shares of company stock valued at $6,683,255 over the last quarter. Corporate insiders own 0.31% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
- Five stocks we like better than Edwards Lifesciences
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
